

WHY CONGRESS SHOULD REGULATE CBD NOW

When Congress passed the 2018 Farm Bill, it explicitly legalized the sale of hemp and its derivatives such as CBD. Farmers across the nation relied on this government action, and invested considerable time and resources to plant, grow, and market commercial hemp crops, and particularly for the market for which there is immediate processing infrastructure and consumer demand: hemp-derived CBD and cannabinoids.

Unfortunately, federal regulatory uncertainty regarding hemp-derived CBD has severely impacted the hemp market, with reduced manufacturing demand resulting in a **more than 90% commodity price decline**, crushing opportunities for U.S. farmers. And while scientific research has demonstrated CBD's strong safety profile – including a 2021 study that addresses concerns about liver toxicity in typical CBD products – FDA has indicated that it will not, on its own, establish a legal pathway for its sale, claiming that current law puts the agency “in a stalemate position.”

The pressing consumer health and safety problem, indeed, is a product of FDA's inaction. Unregulated products being deceptively marketed as hemp or CBD continue to proliferate, some of which raise significant **quality, safety and other consumer protection concerns**. Worse, the commodity price collapse has led some to chemically convert surplus hemp CBD biomass into intoxicating products, such as Delta-8 THC, which are being sold at retail, sometimes to minors. The time for action is now.

There are three legislative vehicles in Congress — **H.R. 841, H.R. 6134, and S. 1698** — that would ensure that hemp-derived CBD could be lawfully marketed. H.R. 841 explicitly legalizes hemp extracts in dietary supplements, while H.R. 6134 explicitly legalizes CBD in foods and beverages. S. 1698 would explicitly legalize CBD in both dietary supplements and foods or beverages. These bills would also require CBD products and hemp extract product manufacturers to comply with the entire existing comprehensive regulatory framework, which ensures that the products are deemed safe, properly labeled and prepared utilizing Good Manufacturing Practices.

Failing to establish a regulatory pathway for legalizing hemp-derived CBD will continue to reduce economic opportunity for U.S. hemp farmers and deny consumers access to safe, quality products. H.R. 841, H.R. 6134, and S. 1698 would **help stabilize the hemp markets**, open up a promising economic opportunity for U.S. agriculture and honor the commitment made to growers in the 2018 Farm Bill.

Once FDA does legally recognize and regulate CBD products, the hemp industry can provide a needed financial jolt to a nation emerging through economic recovery. Regulatory relief for the hemp-derived CBD industry constitutes an **economic stimulus package for the nation's farmers and small businesses** without requiring one dime from the American taxpayer. Independent surveys predict that with a regulatory pathway, sales of CBD products would grow from approximately \$1.2 billion in 2019 to anywhere from \$10.3 billion to \$16.8 billion market by 2025.

Visit regulateCBDnow.com to contact your members of Congress today!

WHY CONGRESS SHOULD REGULATE CBD NOW



The economic urgency for U.S. farmers has heightened as **hemp commodity prices have collapsed by more than 90%** due to regulatory uncertainty.

New scientific research continues to demonstrate **CBD's strong safety profile** – including a 2021 study that addresses FDA's misguided concerns about liver toxicity in CBD products.



FDA officials recognize Congress's interest in moving forward on CBD regulation but claim that current law puts them in a **stalemate position**, unable to take regulatory action.



Unregulated products being deceptively marketed as hemp or CBD continue to proliferate, some of which raise significant concerns. Worse, the price collapse has led some to chemically convert surplus hemp CBD biomass into intoxicating products, such as Delta-8 THC, which are sold at retail, without quality controls, sometimes to minors.

There are three legislative vehicles in Congress with **growing bipartisan support**. HR 841, led by Rep. Kurt Schrader (D-OR) and his Republican cosponsor, Rep. Morgan Griffith (R-VA), is cosponsored by 27 Democrats and 13 Republicans.



Visit regulateCBDnow.com to contact your members of Congress today!

REGULATE CBD NOW

The **Regulate CBD Now** campaign and platform was launched in June 2021 by the U.S. Hemp Roundtable with a coalition of industry leaders and consumers calling on Congress to advocate for legislative vehicles — **H.R. 841, H.R. 6134, and S. 1698** — to establish a regulatory framework for hemp-derived cannabidiol (CBD).

Legislative Vehicles

H.R. 841

Dietary Supplements

Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act



S. 1698

Dietary Supplements Food and Beverages

Hemp Access and Consumer Safety Act




H.R. 6134

Food and Beverages

CBD Product Safety and Standardization Act

What would these bills do?

- Establish a regulatory framework for hemp-derived CBD ensuring that products containing CBD, and other non-intoxicating hemp ingredients, can be lawfully **marketed**.
- Require CBD products and hemp extract **product manufacturers** to comply with existing comprehensive regulatory frameworks to deem all CBD products as safe, properly labeled and prepared utilizing Good Manufacturing Practices.



Visit regulateCBDnow.com to contact your members of Congress today!